Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

6. Kim D. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J. Ovarian Res.. 2024; 17

7. Kim D. Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release. J Cell Sci. 2024; 137

8. Kim D. Minimal information for studies of extracellular vesicles (MISEV 2023): From basic to advanced approaches . Journal of Extracellular Vesicles . 2024; 13 : e12404

9. Kim D. Nanoparticles loaded with IL-2 and TGF-b promote transplantation tolerance to alloantigen. Front. Immunol.. 2024; 15

10. Kang C, Ren X, Lee D, Ramesh R, Nimmo S, Yang-Hartwich Y, Kim D. Harnessing small extracellular vesicles for pro-oxidant delivery: novel approach for drug-sensitive and resistant cancer therapy. Journal of Controlled Release/ELSEVIER. 2024; 365 : 286-300

Grants

6. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2024.

7. Role of Renal Lymphatics in Blood Pressure Regulation. NIH. Start Date: 2018. End Date: 2023.

8. Cancer exosome mediated antibody production for active tumor targeting treatment. Non-federal. Start Date: 2022. End Date: 2023.

9. Engineering Exosome for Ovarian Cancer Targeting Therapy. NIH. Start Date: 2021. End Date: 2023.

10. Exosome based intraocular therapy combined with active targeting of ocular neovascularization. NIH. Start Date: 2022. End Date: 2022.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results